Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024
May 23, 2024 17:00 ET
|
Evaxion Biotech
EVX-01 induced positive clinically relevant immune responses in all assessed patientsBooster immunizations tended to increase the immune responseThe observed immune responses were mediated by both...
Evaxion Receives Nasdaq Notification
May 10, 2024 17:00 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, May 10, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™...
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
April 17, 2024 08:00 ET
|
Evaxion Biotech
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosingFavorable safety profile confirmedTrial on track for one-year clinical efficacy readout in Q3...
Evaxion und nicht offengelegter Kooperationspartner veröffentlichen vielversprechende Ergebnisse für EVX-B1-Impfstoff-Antigene gegen Staphylococcus aureus-Infektionen
April 07, 2024 21:28 ET
|
Evaxion Biotech
Evaxion und sein Kooperationspartner testeten die von Evaxion entwickelten Impfstoff-Antigene gegen Staphylococcus aureus in einem klinisch relevanten Tiermodell für postoperative WundinfektionenDie...
Evaxion et un collaborateur anonyme annoncent des résultats encourageants concernant les antigènes du vaccin EVX-B1 contre l'infection à staphylocoque doré
April 07, 2024 21:28 ET
|
Evaxion Biotech
Evaxion et son collaborateur ont testé les antigènes du vaccin conçus par Evaxion contre le staphylocoque doré sur un modèle animal cliniquement pertinent présentant une infection du site...
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
April 02, 2024 07:00 ET
|
Evaxion Biotech
Evaxion and its collaborator tested Evaxion-designed vaccine antigens against Staphylococcus aureus in a clinically relevant animal model of surgical site infectionsThe vaccine antigens significantly...
Evaxion Announces Business Update and Full Year 2023 Financial Results
March 27, 2024 07:30 ET
|
Evaxion Biotech
Precision vaccine project initiated with the ambition to obtain Preclinical Proof-of-Concept by H2 2024. The novel concept entails AI-identification of a new class of cancer vaccine targets, named...
Evaxion veranstaltet F&E-Tag und stellt das breite Potenzial seiner AI-Immunology™-Plattform vor
March 20, 2024 06:23 ET
|
Evaxion Biotech
Die unternehmenseigene AI-Immunology™-Plattform bietet das Potenzial für eine neue Ära der Entdeckung, des Designs und der Entwicklung von Impfstoffen mithilfe fortschrittlicher KI- und maschineller...
Evaxion organise la journée de la recherche et développement et dévoile le vaste potentiel de sa plateforme AI-Immunology™
March 20, 2024 06:23 ET
|
Evaxion Biotech
La plateforme AI-Immunology™ brevetée ouvre la voie d'une nouvelle ère dans le monde de la découverte, de la conception et du développement de vaccins grâce à des technologies avancées d'IA et...
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
March 19, 2024 07:30 ET
|
Evaxion Biotech
The proprietary AI-Immunology™ platform brings the potential for a new era in vaccine discovery, design and development using advanced AI and machine learning technologiesAI-Immunology™ outcompetes...